CELG-RI — BRISTOL MYERS SQUIBB CO
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 14272 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 11,489,000,000 | 8,068,000,000 | -5,600,000,000 | 2,677,000,000 | 86,476,000,000 | 9,574,000,000 | 66,374,000,000 |
| Sep 2025 | 12,222,000,000 | 8,787,000,000 | -4,638,000,000 | 2,201,000,000 | 96,889,000,000 | 15,726,000,000 | 78,289,000,000 |
| Jun 2025 | 12,269,000,000 | 8,897,000,000 | -6,228,000,000 | 1,310,000,000 | 94,676,000,000 | 12,599,000,000 | 77,187,000,000 |
| Mar 2025 | 11,201,000,000 | 8,168,000,000 | -5,059,000,000 | 2,456,000,000 | 92,427,000,000 | 10,875,000,000 | 74,979,000,000 |
Annual Trend (SEC EDGAR, last 10y)
Revenues vs Net Income (last 10y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,194,000,000 | -27,839,000,000 | 7,054,000,000 | 90,038,000,000 | 71,533,000,000 | 18,506,000,000 | — |
| Dec 2024 | 48,300,000,000 | -54,990,000,000 | -8,948,000,000 | 92,603,000,000 | 76,215,000,000 | 16,388,000,000 | — |
| Dec 2023 | 45,006,000,000 | -29,849,000,000 | 8,025,000,000 | 95,159,000,000 | 65,674,000,000 | 29,485,000,000 | — |
| Dec 2022 | 46,159,000,000 | -30,650,000,000 | 6,327,000,000 | 96,820,000,000 | 65,702,000,000 | 31,118,000,000 | — |
| Dec 2021 | 46,385,000,000 | -32,820,000,000 | 6,994,000,000 | 109,314,000,000 | 73,308,000,000 | 36,006,000,000 | — |
| Dec 2020 | 42,518,000,000 | -48,053,000,000 | -9,015,000,000 | 118,481,000,000 | 80,599,000,000 | 37,882,000,000 | — |
| Dec 2019 | 26,145,000,000 | -17,031,000,000 | 3,439,000,000 | 129,944,000,000 | 78,246,000,000 | 51,698,000,000 | — |
| Dec 2018 | 22,561,000,000 | -12,459,000,000 | 4,920,000,000 | 34,986,000,000 | 20,859,000,000 | 14,127,000,000 | — |
| Dec 2017 | 20,776,000,000 | -13,353,000,000 | 1,007,000,000 | 33,551,000,000 | 21,704,000,000 | 11,847,000,000 | — |
| Dec 2016 | 19,427,000,000 | -9,577,000,000 | 4,457,000,000 | 33,707,000,000 | 17,360,000,000 | 16,347,000,000 | — |
TTM Snapshot
Revenues TTM
$48,482,000,000
NetIncome TTM
$7,275,000,000
OpCashFlow TTM
—
Assets (Latest)
$86,476,000,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.04T | $1169.60 | — |
| JNJ | JOHNSON & JOHNSON | $618.09B | $256.48 | — |
| ABBV | AbbVie Inc. | $481.40B | $272.42 | — |
| MRK | Merck & Co., Inc. | $351.28B | $142.38 | — |
| NVS | NOVARTIS AG | $272.01B | $143.11 | — |
News headlines (Yahoo Finance, 1h cache)
Does The Move In Merck Stock Change Anything?
2026-10-09 18:12 · Yahoo
Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning
2026-10-09 17:45 · Yahoo
What Could Bristol Myers Squibb (BMY) Phase 3 Myeloma Data Mean For Investors?
2026-10-09 17:15 · Yahoo
2 Profitable Stocks to Target This Week and 1 We Find Risky
2026-10-09 10:35 · Yahoo
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
2026-10-09 01:03 · Yahoo
Should You Be Worried About Pfizer Stock?
2026-10-09 00:36 · Yahoo
What Is Going On With Regeneron Stock?
2026-10-09 00:19 · Yahoo
BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
2026-10-08 16:55 · Yahoo
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
2026-10-08 15:10 · Yahoo
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
2026-10-08 14:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.